MECOM and leukemia: MiR-133 downregulates Ecotropic viral integration site 1 (Evi1) in leukemic cells, increasing treatment sensitivity, according to Yamamoto et al. As a result, it is feasible that miR-133 might be used to treat leukemias that overexpress Evi1 [26].